Sympathetic overactivity occurs before hypertension in the two-kidney, one-clip model

Experimental Physiology

Volumn 101, Issue 1, 2016, Pages 67-80

  Oliveira Sales, Elizabeth B ^a,b   Colombari, Eduardo ^a,c   Abdala, Ana Paula ^a   Campos, Ruy R ^b   Paton, Julian F R ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTERY CLAMP; ARTICLE; BRAIN STEM; CARDIOVASCULAR PARAMETERS; CHEMORECEPTOR; CHEMORECEPTOR REFLEX; CONTROLLED STUDY; HEART; HEART RATE; HYPERTENSION; KIDNEY ARTERY; MALE; NERVE CONDUCTION; NONHUMAN; PERFUSION PRESSURE; PHRENIC NERVE; PRESSORECEPTOR REFLEX; RAT; SPINAL CORD TRANSSECTION; SYMPATHETIC NERVE; SYMPATHETIC TONE;

EID: 84978472757     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/EP085390     Document Type: Article

References (65)

1. Ackland GL, Kazymov V, Marina N, Singer M & Gourine AV (2013). Peripheral neural detection of danger-associated and pathogen-associated molecular patterns. Crit Care Med 41, 85–92.
2. 1 receptor-mediated excitation of rat carotid body chemoreceptor afferent activity. J Physiol 510, 773–781.
3. Antunes VR, Yao ST, Pickering AE, Murphy D & Paton JFR (2006). A spinal vasopressinergic mechanism mediates hyperosmolality-induced sympathoexcitation. J Physiol 576, 569–583.
4. Barnes JN, Hart EC, Curry TB, Nicholson WT, Eisenach JH, Wallin BG, Charkoudian N & Joyner MJ (2014). Aging enhances autonomic support of blood pressure in women. Hypertension 63, 303–308.
5. Biancardi VC, Son SJ, Ahmadi S, Filosa JA & Stern JE (2014). Circulating angiotensin II gains access to the hypothalamus and brain stem during hypertension via breakdown of the blood–brain barrier. Hypertension 63, 572–579.
6. Brody MJ & Johnson AK (1980). Role of the anteroventral third ventricle region in fluid and electrolyte balance, arterial pressure regulation, and hypertension. In Frontiers in Neuroendocrinology, ed. Martini L, Ganong WF, pp. 249–292. Raven Press, New York.
7. Burke SL, Evans RG & Head GA (2010). Effects of chronic sympatho-inhibition on reflex control of renal blood flow and plasma renin activity in renovascular hypertension. Br J Pharmacol 159, 438–448.
8. Campese VM, Ye SO, Zhong H, Yanamadala V, Ye Z & Chiu J (2004). Reactive oxygen species stimulate central and peripheral sympathetic nervous system activity. Am J Physiol Heart Circ Physiol 287, H695–H703.
9. Campos RR, Oliveira-Sales EB, Nishi EE, Paton JFR & Bergamaschi CT (2015). Mechanisms of renal sympathetic activation in renovascular hypertension. Exp Physiol 100, 496–501.
10. Colombari E, Colombari DS, Sumners C, Raizada MK, Murphy D & Paton JFR (2010). Macrophage migration inhibitory factor in hypothalamic paraventricular nucleus neurons decreases symapthoexcitatory responses to hyperosmotic stimuli in situ. Hypertension 56, 956–963.
11. de Oliveira-Sales EB, Nishi EE, Boim MA, Dolnikoff MS, Bergamaschi CT & Campos RR (2010). Upregulation of AT1R and iNOS in the rostral ventrolateral medulla (RVLM) is essential for the sympathetic hyperactivity and hypertension in the 2K-1C Wistar rat model. Am J Hypertens 23, 708–715.
12. Dibona GF & Kopp UC (1997). Neural control of renal function. Physiol Rev 77, 75–197.
13. Edmunds ME, Russel GI & Bing RF (1991). Reversal of experimental renovascular hypertension. Hypertension 9, 289–301.
14. Elliott WJ (2007). Secondary hypertension: renovascular hypertension. In Hypertension: a Companion to Braunwald's Heart Disease, ed. Black H & Elliott WG, pp. 93–105. Sanders-Elsevier, Philadelphia.
15. Esler M, Lambert E & Schlaich M (2010). Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension. J Appl Physiol 109, 1996–1998.
16. Faber JE & Brody MJ (1983). Neural contribution to renal hypertension following acute renal artery stenosis in conscious rats. Hypertension 5, 155–164.
17. Ferguson AV (2009). Angiotensinergic regulation of autonomic and neuroendocrine outputs: critical roles for the subfornical organ and paraventricular nucleus. Neuroendocrinology 89, 370–376.
18. Goldblatt H, Lynch J, Hanzal RF & Summerville WW (1934). Studies on experimental hypertension. 1. The production of persistent elevation systolic blood pressure by means of renal ischemia. J Exp Med 59, 347–378.
19. Grassi G (2004a). Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens 13, 513–519.
20. Grassi G (2004b). Sympathetic and baroreflex function in hypertension: implications for current and new drugs. Curr Pharm Des 10, 3579–3589.
21. Grundy D (2015). Principles and standards for reporting animal experiments in The Journal of Physiology and Experimental Physiology. Exp Physiol 100, 755–758.
22. Head GA & Burke SL (2004). Sympathetic responses to stress and rilmenidine in 2K1C rabbits. Evidence of enhanced nonvascular effector mechanism. Hypertension 43, 636–642.
23. Johansson M, Elam M, Rundqvist B, Eisenhofer G, Herlitz H, Lambert G & Friberg P (1999). Increased sympathetic nerve activity in renovascular hypertension. Circulation 99, 2537–2542.
24. Johnson AK, Zhang Z, Clayton SC, Beltz TG, Hurley SW, Thunhort RL & Xue B (2015). The roles of sensitization and neuroplasticity in the long-term regulation of blood pressure and hypertension. Am J Physiol Regul Integr Comp Physiol 30, R1309–R1325.
25. Kasparov S, Butcher JW & Paton JFR (1998). Angiotensin II receptors within the nucleus of the solitary tract attenuate the baroreceptor vagal reflex in pre-weaned rats. J Auton Nerv Syst 74, 160–168.
26. Katholi RE, Winternitz SR & Oparil S (1982). Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat. J Clin Invest 69, 55–62.
27. Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R & Esler MD (2014). Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet 383, 622–629.
28. Ku YH, Jia YF & Chang YZ (1999). Mechanisms underlying pressor response of subfornical organ to angiotensin II. Peptides 20, 171–176.
29. Lam SY & Leung PS (2002). A locally generated angiotensin system in rat carotid body. Regul Pept 107, 97–103.
30. Lerman LO, Chade AR, Sica V & Napoli C (2005). Animal models of hypertension: an overview. J Lab Clin Med 146, 160–173.
31. McBryde FD, Abdala AP, Hendy EB, Pijacka W, Marvar P, Moraes DJ, Sobotka PA & Paton JF (2013). The carotid body as a putative therapeutic target for the treatment of neurogenic hypertension. Nat Commun 4, 2395.
32. McElroy ND & Zimmerman BG (1989). Characterization of intrarenal arterial adrenergic receptors in renovascular hypertension. Hypertension 13, 851–858.
33. Mahfoud F, Tunev S, Ruwart J, Schulz-Jander D, Cremers B, Linz D, Zeller T, Bhatt DL, Rocha-Singh K, Böhm M & Melder RJ (2014). Efficacy and safety of catheter-based radiofrequency renal denervation in stented renal arteries. Circ Cardiovasc Interv 7, 813–820.
34. Marvar PJ, Thabet SR, Guzik TJ, Lob HE, McCann LA, Weyand C, Gordon FJ & Harrison DG (2010). Central and peripheral mechanisms of T-lymphocyte activation and vascular inflammation produced by angiotensin II-induced hypertension. Circ Res 107, 263–270.
35. Melaragno MG & Fink GD (1996). Slow pressor effect of angiotensin II in normotensive rats with renal artery stenosis. Clin Exp Pharmacol Physiol 23, 140–144.
36. Mitchell KD & Navar LG (1995). Intrarenal actions of angiotensin II in the pathogenesis of experimental hypertension. In Hypertension: Pathophysiology, Diagnosis, and Management, ed. Laragh JH & Brenner BM, pp. 1437–1450. Raven, New York.
37. Miyajima E, Yamada Y, Yoshida Y, Matsukawa T, Shionoiri H, Tochikubo O & Ishii M (1991). Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension 17, 1057–1062.
38. Moraes DJA, Machado BH & Paton JFR (2014). Specific respiratory neuron types have increased excitability that drive pre-sympathetic neurones in neurogenic hypertension. Hypertension 63, 1309–1318.
39. Nakada T, Kubota Y, Suzuki H, Sasagawa I, Watanabe M & Ishigooka M (1996). Supression of sympathetic nervous system attenuates the development of two-kidney, one-clip Goldblatt hypertension. J Urol 156, 1480–1484.
40. Navar LG (2010). Counterpoint: Activation of the intrarenal renin-angiotensin system is the dominant contributor to systemic hypertension. J Appl Physiol 109, 1998–2000.
41. Navar LG, Zou L, Thun AV, Wang CT, Iming JD & Mitchell KD (1998). Unraveling the mystery of Goldblatt hypertension. News Physiol Sci 13, 170–176.
42. Nishi EE, Bergamaschi CT, Oliveira-Sales EB, Simon KA & Campos RR (2013). Losartan reduces oxidative stress within the rostral ventrolateral medulla of rats with renovascular hypertension. Am J Hypertens 26, 858–865.
43. Oliveira-Sales EB, Colombari DSA, Davisson RL, Kasparov S, Hirata AE, Campos RR & Paton JFR (2010). Kidney-induced hypertension depends on superoxide signaling in the rostral ventrolateral medulla. Hypertension 56, 290–296.
44. Oliveira-Sales EB, Dugaich AP, Carillo BA, Abreu NP, Boim MA, Dolnikoff MS, Bergamaschi CT & Campos RR (2008). Oxidative stress contributes to renovascular hypertension. Am J Hypertens 21, 98–104.
45. Oliveira-Sales EB, Toward MA, Campos RR & Paton JF (2014). Revealing the role of the autonomic nervous system in the development and maintenance of Goldblatt hypertension in rats. Auton Neurosci 183, 23–29.
46. Papademetriou V, Doumas M, Anyfanti P, Faselis C, Kokkinos P & Tsioufis C (2014). Renal nerve ablation for hypertensive patients with chronic kidney disease. Curr Vasc Pharmacol 12, 47–54.
47. Paton JFR (1996). A working heart-brainstem preparation of the mouse. J Neurosci Methods 65, 63–68.
48. Paton JFR & Kasparov S (1999). Differential effects of angiotensin II on cardiovascular reflexes mediated by nucleus tractus solitarii – a microinjection study in the rat. J Physiol 521, 213–225.
49. 2 sensing mediate hypertension and pulmonary edema. Proc Natl Acad Sci USA 111, 1174–1179.
50. Persu A, Jin Y, Baelen M, Vink E, Verloop WL, Schmidt B et al. (2014). European Network Coordinating research on Renal Denervation Consortium. Eligibility for renal denervation: experience at 11 European expert centers. Hypertension 63, 1319–1325.
51. Ploth DW (1983). Angiotensin-dependent renal mechanisms in two-kidney one-clip renal vascular hypertension. Am J Physiol Renal Physiol 245, F131–F141.
52. Polson JW, Boscan P, Pickering AE, Dampney RAL & Paton JFR (2007). Differential baroreflex control of sympathetic drive by angiotensin II in nucleus tractus solitarii. Am J Physiol Regul Integr Comp Physiol 293, R1954–R1960.
53. Ratcliffe LEK, Pijacka W, McBryde FD, Abdala AP, Moraes DJ, Sobotka PA, Hart EC, Narkiewicz K, Nightingale AK & Paton JFR (2014). CrossTalk opposing view: Which technique for controlling resistant hypertension? Carotid chemoreceptor denervation/modulation. J Physiol 592, 3941–3944.
54. St-John WM & Paton JFR (2003). Defining eupnea. Respir Physiol Neurobiol 139, 97–103.
55. Simms AE, Paton JFR & Pickering AE (2007). Hierarchical recruitment of the sympathetic and parasympathetic limbs of the baroreflex in normotensive and spontaneously hypertensive rats. J Physiol 579, 473–486.
56. Simms AE, Paton JFR, Pickering AE & Allen AM (2009). Amplified respiratory–sympathetic coupling in neonatal and juvenile spontaneously hypertensive rats: does it contribute to hypertension? J Physiol 587, 597–610.
57. Smith PA, Graham LN, Mackintosh AF, Stoker JB & Mary DASG (2004). Relationship between central sympathetic activity and stages of human hypertension. Am J Hypertens 17, 217–222.
58. Smith PA, Graham LN, Mackintosh AF, Stoker JB & Mary DASG (2002). Sympathetic neural mechanisms in white-coat hypertension. J Am Coll Cardiol 40, 126–132.
59. Somers VK, Mark AL & Abboud FM (1988). Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Hypertension 11, 608–612.
60. 1 receptors in the nucleus tractus solitarius. Am J Physiol Regul Integr Comp Physiol 293, R2267–R2278.
61. Tan ZY, Lu Y, Whiteis CA, Simms AE, Paton JFR, Chapleau MW & Abboud FM (2010). Chemoreceptor hypersensitivity, sympathetic excitation, and overexpression of ASIC and TASK channels before the onset of hypertension in SHR. Circ Res 106, 536–545.
62. 2 and pH of the working heart-brain stem preparation during vascular with aqueous medium. Am J Physiol Regul Integr Comp Physiol 281, R528–R538.
63. Zoccal DB, Simms AE, Bonagamba LH, Braga VA, Pickering AE, Machado BH & Paton JFR (2008). Increased sympathetic outflow in juvenile rats submitted to chronic intermittent hypoxia correlates with enhanced expiratory activity. J Physiol 586, 3253–3265.
64. Zubcevic J, Santisteban MM, Pitts T, Baekey DM, Perez PD, Bolser DC, Febo M & Raizada MK (2014). Functional neural–bone marrow pathways: implications in hypertension and cardiovascular disease. Hypertension 63, 129–139.
65. Zubcevic J, Waki H, Raizada MK & Paton JFR (2011). Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension. Hypertension 57, 1026–1033.